[Evolution of the interventional reperfusion strategy and reperfusion times in acute ST-segment elevation myocardial

S Azzaz1, C Charbonnel1, B Ajlani1

  • 1Unité de soins intensifs cardiologiques et cardiologie interventionnelle, service de cardiologie, hôpital André-Mignot, 177, rue de Versailles, 78157 Le Chesnay cedex, France.

Annales De Cardiologie Et D'Angeiologie
|October 8, 2015
PubMed

Insights

Achieving recommended reperfusion times for ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI) improved significantly between 2007 and 2012. This enhancement in STEMI treatment times was linked to better inter-team coordination and updated protocols.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Emergency Medicine

Background:

  • Primary percutaneous coronary intervention (pPCI) is the standard treatment for ST-segment elevation myocardial infarction (STEMI).
  • Recommended reperfusion times, including first medical contact-to-balloon (M2B) and door-to-balloon (D2B), are frequently not met in STEMI patients.
  • Less than 50% of STEMI patients achieve guideline-adherent reperfusion times.

Purpose of the Study:

  • To compare reperfusion strategies and times in STEMI patients undergoing pPCI.
  • To evaluate changes in STEMI treatment times between 2007 and 2012.

Main Methods:

  • Retrospective analysis of 182 STEMI patients treated with pPCI within 12 hours of symptom onset.
  • Comparison of procedural characteristics and reperfusion times between two cohorts: 2007-2008 (Period 1) and 2012 (Period 2).
  • Non-parametric statistical tests were used for comparison.

Main Results:

  • The median M2B time decreased by 26% from 135 minutes in 2007 to 100 minutes in 2012 (P<0.001).
  • The median D2B time also significantly decreased from 51 minutes to 44 minutes (P<0.01).
  • Increased use of radial access, thromboaspiration, drug-eluting stents, and reduced incidence of cardiogenic shock were observed in 2012.

Conclusions:

  • Reperfusion times (D2B and M2B) significantly improved between 2007 and 2012, with over 60% of patients meeting recommended goals.
  • Improved coordination between emergency medical services and interventional cardiology teams likely contributed to the reduced times.
  • Implementation of 24/7 paramedic presence in catheterization labs, as per French regulation, may have enhanced pPCI efficiency.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
467
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.7K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.3K